Remove 2015 Remove Packaging Remove Pharmaceutical Companies
article thumbnail

Innovation across the healthcare system is needed to realise the value of medicines

pharmaphorum

From patients, patient bodies, pharmaceutical companies, and academia, to regulatory bodies, public institutions, and small and medium-sized enterprises (SMEs), all key stakeholders must come together to help the patients who most need new medicines to access them as quickly as possible. About the author.

article thumbnail

COVID-19: Celltrion’s therapeutic option

pharmaphorum

“As a company, we felt well-placed to develop a therapeutic option against COVID-19 as we have experience in developing therapeutics for similar viruses,” says Ki-sung. “We This really tested pharmaceutical companies,” explains Ki-Sung. We found that strong and open channels of communication were imperative.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Enabling the leaders of the future

pharmaphorum

iii] It’s no longer just about the company, compensation package and secondary benefits (e.g., Mark Larsen is vice president and head of human resources for Europe, Middle East and Africa (EMEA) at Janssen, the Pharmaceutical Companies of Johnson & Johnson. gym membership).

article thumbnail

Fixed-dose combination: Considerations for design, formulation, manufacturing and analysis

Pharmaceutical Technology

Pharmaceutical companies – and the FDA – are embracing FDCs. Between 2010 and the end of 2015, of the 655 New Drug Applications (NDAs) approved by the FDA, 63 were for FDCs. The potential to extend the patent life and market exclusivity of a company’s APIs is a potent financial incentive. The numbers tell the story.

article thumbnail

Digital investment promises to accelerate the use of wearable sensor data in clinical trials

pharmaphorum

Garabedian and his team plan to support VivoSense, not just with their funding package but with their industry network and connectivity. “We If pharmaceutical companies do not use this data, someone else will. This brings us to VivoSense. We believe that VivoSense is ‘the tip of the spear’ in this category.”.

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

All traditional small molecule pharmaceuticals include carbon building blocks – by definition, organic materials – which are then transformed via modern synthetic chemistry to assemble the complex and highly variable skeletons that the final target structures demand. In 2015 he joined the Process Chemistry & Catalysis group at F.

article thumbnail

Are microtaggants the key to making medicines smarter?

pharmaphorum

Pharmaceutical companies are accountable for ensuring that their medicine is safe when it comes into the hands of patients. Many countries have introduced serialisation legislation which requires product identifiers to be affixed to each package to provide traceability throughout the distribution supply chain.